Cargando…
DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia
BACKGROUND: DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying...
Autores principales: | Kim, Stephanie S., Lee, Seung Cho, Lim, Bumjin, Shin, Seung-Ho, Kim, Mee Young, Kim, Sol-Yi, Lim, Hyeyeun, Charton, Clémentine, Shin, Dongho, Moon, Hyong Woo, Kim, Jinho, Park, Donghyun, Park, Woong-Yang, Lee, Ji Youl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318333/ https://www.ncbi.nlm.nih.gov/pubmed/37409096 http://dx.doi.org/10.1016/j.prnil.2023.01.001 |
Ejemplares similares
-
Expression and Localization of Aquaporins in Benign Prostate Hyperplasia and Prostate Cancer
por: Hwang, Insang, et al.
Publicado: (2012) -
Changes in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia
por: Lee, Chang Ju, et al.
Publicado: (2010) -
Technical Aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia
por: Kim, Myong, et al.
Publicado: (2013) -
Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018) -
Urinary exosomal microRNA profiling in intermediate-risk prostate cancer
por: Kim, Mee Young, et al.
Publicado: (2021)